ACD 101

Drug Profile

ACD 101

Alternative Names: 124I-ACD-101; 131I-ACD-101; ACD-101

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Amino acids; Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Apoptosis stimulants; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Glioma

Most Recent Events

  • 19 Jan 2017 Telix Pharmaceuticals enters into a partnership with Therapeia GmbH to acquire ACD 101 theranostic program for glioblastoma
  • 18 Jan 2017 Clinical trials in Glioma in Europe (IV)
  • 04 Mar 2016 ACD 101 is available for licensing - http://www.therapeia.info/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top